News coverage about Teleflex (NYSE:TFX) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teleflex earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 46.71800860136 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Several research firms have commented on TFX. BidaskClub cut Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday. Jefferies Group LLC restated a “buy” rating and issued a $230.00 price target on shares of Teleflex in a report on Thursday, August 3rd. Needham & Company LLC restated a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Deutsche Bank AG restated a “buy” rating and issued a $238.00 price target (up previously from $220.00) on shares of Teleflex in a report on Wednesday. Finally, Zacks Investment Research cut Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $228.00.

Shares of Teleflex (NYSE TFX) traded up 0.82% during mid-day trading on Friday, hitting $205.34. The stock had a trading volume of 202,230 shares. Teleflex has a one year low of $136.53 and a one year high of $217.97. The firm has a market cap of $9.25 billion, a price-to-earnings ratio of 39.27 and a beta of 1.05. The company has a 50-day moving average of $209.38 and a 200 day moving average of $196.62.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.91 by $0.13. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The company had revenue of $528.60 million during the quarter, compared to the consensus estimate of $518.98 million. During the same period last year, the business earned $1.89 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities research analysts forecast that Teleflex will post $8.28 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, August 11th. Teleflex’s dividend payout ratio (DPR) is presently 26.00%.

In other news, Director Stephen K. M.D. Klasko sold 5,200 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $193.56, for a total transaction of $1,006,512.00. Following the completion of the sale, the director now directly owns 12,880 shares of the company’s stock, valued at approximately $2,493,052.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stuart A. Randle sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $205.67, for a total value of $514,175.00. Following the sale, the director now directly owns 7,532 shares of the company’s stock, valued at $1,549,106.44. The disclosure for this sale can be found here. Insiders have sold a total of 8,300 shares of company stock valued at $1,643,975 over the last ninety days. Company insiders own 2.39% of the company’s stock.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Teleflex (NYSE:TFX) Stock Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-teleflex-nysetfx-stock-price/1475973.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.